OXFORD, UK – 22 November 2023 – PrecisionLife®, a leading computational biology company focused on precision medicine in complex chronic diseases, announces the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare.
Gerald joins PrecisionLife as SVP Corporate Development working across both biopharma and healthcare. Gerald is a molecular biologist who received his PhD in Antimicrobial Drug Discovery under the Glaxo Scholarship Program. After several years…
Following a period of sustained growth, life science logistics company Biocair has relocated and expanded its Chicago office and warehouse facility. As part of its wider global growth strategy, the leading specialist has increased its 2,904 sq. ft. space by more than double, securing a new 7,213 sq. ft. facility just three miles from the key cargo complex at O’Hare International Airport.
The facility will house certified packaging and conditioning areas for a wide range of temperatures, including an advanced liquid nitrogen service station and office space for operations staff. Biocair first…
New 60,000 sq ft multi-occupancy building will provide additional space for life science companies within Cambridge cluster
Cambridge, UK, 20th November 2023: Chesterford Research Park, one of the leading life science centres in the UK, which is owned by Aviva Investors, the global asset management business of Aviva plc, alongside Uttlesford District Council, has announced it has begun construction of an additional 60,000 sq ft of facilities at its new Sidney Sussex Building.
The project will be delivered by Readie Construction which has been appointed main contractor for the…
Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)
AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN).
• Astex is eligible to receive a milestone payment and royalties on sales of the new drug under its 2005 collaboration…
Excellent to see Charles River, a Partner of One Nucleus, making progress (5 years ahead of schedule!) towards helping achieve 100% renewable electricity globally. Read more to find out how...
Arecor Therapeutics plc
(“Arecor” or the “Group”)
FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE
First commercial sale triggers milestone payment and future royalties to Arecor
Cambridge, UK, 17 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces the triggering of a milestone payment from its global pharmaceutical partner, following the first commercial sale of a product, AT220, incorporating its proprietary Arestat™ technology platform.
Sarah Howell, Chief…
Bristol Myers Squibb's (BMS) Augtyro (repotrectinib) has been approved by the US Food and Drug Administration (FDA) to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer deaths in the US, with NSCLC representing up to 85% of all lung cancer diagnoses.
More common in individuals with little to no smoking history, the ROS1 gene alteration occurs in only up to 2% of NSCLC patients and is associated with aggressive lung cancer that can often spread to the brain.
Augtyro, which is a tyrosine kinase…
The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, are delighted to announce the construction of a new Health Innovation Hub in Govan, setting the stage for a thriving life sciences cluster in the area.
Work on the new Health Innovation Hub has begun, and is due for completion in summer 2025. Morrison Construction have been appointed as the main contractor. The Hub will attract new innovative businesses into the area, and deliver local benefits to the community through job creation.
The Hub is a flagship investment within the University’s Glasgow Riverside…
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund
Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines
15 November 2023; Cambridge, England – T-Therapeutics (“the Company”), a biotechnology company developing next-generation TCR therapeutics designed to reshape the clinical landscape for cancer patients, today announces it has raised £48 million ($59 million) in a Series A…
Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy
Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.
Most recently, Tony held the position of Chief Executive Officer at Goldfinch…